Related Experiment Video
Updated: Jun 14, 2025
06:32
Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
Published on: January 9, 2019
7.8K
Prognostic Factors for Patients with Primary Gliosarcoma: A Single-Center Retrospective Study
Chen Li1, Wenqian Zhou2, Peng Wang3
1Department of Neurosurgery, The Second Affiliated Hospita of Air Force Medical University, Xian, China.
World Neurosurgery
|August 31, 2024
Summary
Optimal management of primary gliosarcoma involves complete resection, adjuvant therapy, and salvage treatment for recurrence. Careful monitoring for metastases is crucial during treatment for this rare brain tumor.
Area of Science:
- Neuro-oncology
- Central Nervous System Tumors
- Malignant Brain Tumors
Background:
- Primary gliosarcoma is a rare, aggressive central nervous system tumor.
- Prognostic factors and effective treatments remain poorly understood.
- Limited research exists on the determinants of survival and therapeutic strategies.
Purpose of the Study:
- To identify prognostic determinants for primary gliosarcoma.
- To evaluate effective therapeutic interventions for this rare tumor.
- To analyze survival outcomes based on treatment and patient characteristics.
Main Methods:
- Retrospective analysis of 77 primary gliosarcoma patients (March 2011-June 2023).
- Exclusion of patients with prior glioma history or preoperative chemoradiotherapy.
- Kaplan-Meier and Cox regression analyses for survival prediction.
Main Results:
- Complete resection, age ≤65 years, Ki67 ≤25%, Karnofsky Performance Status ≥70, Stupp protocol adherence, and salvage therapy predicted better survival.
- Complete resection, younger age, Stupp protocol, and salvage therapy were independent predictors of overall survival.
- One case of subcutaneous metastasis was observed during treatment.
Conclusions:
- Maximal safe resection followed by adjuvant radiotherapy and chemotherapy (temozolomide) is recommended.
- Salvage therapy for recurrent gliosarcoma improves outcomes.
- Vigilant monitoring for potential metastases during treatment is essential.
